These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 20042100)

  • 1. Design and pre-clinical profiling of a Plasmodium falciparum MSP-3 derived component for a multi-valent virosomal malaria vaccine.
    Tamborrini M; Mueller MS; Stoffel SA; Westerfeld N; Vogel D; Boato F; Zurbriggen R; Robinson JA; Pluschke G
    Malar J; 2009 Dec; 8():314. PubMed ID: 20042100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.
    Tamborrini M; Stoffel SA; Westerfeld N; Amacker M; Theisen M; Zurbriggen R; Pluschke G
    Malar J; 2011 Dec; 10():359. PubMed ID: 22166048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical profiling of the immunogenicity of a two-component subunit malaria vaccine candidate based on virosome technology.
    Okitsu SL; Mueller MS; Amacker M; Vogel D; Westerfeld N; Robinson JA; Zurbriggen R; Pluschke G
    Hum Vaccin; 2008; 4(2):106-14. PubMed ID: 18382133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
    Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1.
    Mueller MS; Renard A; Boato F; Vogel D; Naegeli M; Zurbriggen R; Robinson JA; Pluschke G
    Infect Immun; 2003 Aug; 71(8):4749-58. PubMed ID: 12874357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies elicited by a virosomally formulated Plasmodium falciparum serine repeat antigen-5 derived peptide detect the processed 47 kDa fragment both in sporozoites and merozoites.
    Okitsu SL; Boato F; Mueller MS; Li DB; Vogel D; Westerfeld N; Zurbriggen R; Robinson JA; Pluschke G
    Peptides; 2007 Oct; 28(10):2051-60. PubMed ID: 17875342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of influenza immunity and virosomal-formulated synthetic peptide to cellular immune responses in a phase I subunit malaria vaccine trial.
    Peduzzi E; Westerfeld N; Zurbriggen R; Pluschke G; Daubenberger CA
    Clin Immunol; 2008 May; 127(2):188-97. PubMed ID: 18337175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers.
    Genton B; Pluschke G; Degen L; Kammer AR; Westerfeld N; Okitsu SL; Schroller S; Vounatsou P; Mueller MM; Tanner M; Zurbriggen R
    PLoS One; 2007 Oct; 2(10):e1018. PubMed ID: 17925866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A virosomal malaria peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a clinical trial.
    Okitsu SL; Silvie O; Westerfeld N; Curcic M; Kammer AR; Mueller MS; Sauerwein RW; Robinson JA; Genton B; Mazier D; Zurbriggen R; Pluschke G
    PLoS One; 2007 Dec; 2(12):e1278. PubMed ID: 18060072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The antibody response to Plasmodium falciparum Merozoite Surface Protein 4: comparative assessment of specificity and growth inhibitory antibody activity to infection-acquired and immunization-induced epitopes.
    de Silva HD; Saleh S; Kovacevic S; Wang L; Black CG; Plebanski M; Coppel RL
    Malar J; 2011 Sep; 10():266. PubMed ID: 21920045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative testing of six antigen-based malaria vaccine candidates directed toward merozoite-stage Plasmodium falciparum.
    Arnot DE; Cavanagh DR; Remarque EJ; Creasey AM; Sowa MP; Morgan WD; Holder AA; Longacre S; Thomas AW
    Clin Vaccine Immunol; 2008 Sep; 15(9):1345-55. PubMed ID: 18550731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintaining immunogenicity of blood stage and sexual stage subunit malaria vaccines when formulated in combination.
    Parzych EM; Miura K; Long CA; Burns JM
    PLoS One; 2020; 15(4):e0232355. PubMed ID: 32348377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasmodium falciparum merozoite surface protein 1 (MSP-1)-MSP-3 chimeric protein: immunogenicity determined with human-compatible adjuvants and induction of protective immune response.
    Mazumdar S; Mukherjee P; Yazdani SS; Jain SK; Mohmmed A; Chauhan VS
    Infect Immun; 2010 Feb; 78(2):872-83. PubMed ID: 19933832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and in vitro protective efficacy of recombinant Mycobacterium bovis bacille Calmette Guerin (rBCG) expressing the 19 kDa merozoite surface protein-1 (MSP-1(19)) antigen of Plasmodium falciparum.
    Nurul AA; Norazmi MN
    Parasitol Res; 2011 Apr; 108(4):887-97. PubMed ID: 21057812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
    Lalitha PV; Biswas S; Pillai CR; Saxena RK
    Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity-based design of a synthetic malaria peptide eliciting sporozoite inhibitory antibodies in a virosomal formulation.
    Okitsu SL; Kienzl U; Moehle K; Silvie O; Peduzzi E; Mueller MS; Sauerwein RW; Matile H; Zurbriggen R; Mazier D; Robinson JA; Pluschke G
    Chem Biol; 2007 May; 14(5):577-87. PubMed ID: 17524988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production and preclinical evaluation of Plasmodium falciparum MSP-119 and MSP-311 chimeric protein, PfMSP-Fu24.
    Gupta PK; Mukherjee P; Dhawan S; Pandey AK; Mazumdar S; Gaur D; Jain SK; Chauhan VS
    Clin Vaccine Immunol; 2014 Jun; 21(6):886-97. PubMed ID: 24789797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and efficacy trials in Aotus nancymai monkeys with model compounds representing parts of a 75-kD merozoite surface antigen of Plasmodium falciparum.
    Sharma P; Ruebush TK; Campbell GH; Richman SJ; Wilkins PP; Broderson JR; Ardeshir F; Gross M; Silverman C; Skinner JC
    Am J Trop Med Hyg; 1992 Jun; 46(6):691-707. PubMed ID: 1621894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine.
    Pöltl-Frank F; Zurbriggen R; Helg A; Stuart F; Robinson J; Glück R; Pluschke G
    Clin Exp Immunol; 1999 Sep; 117(3):496-503. PubMed ID: 10469053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Plasmodium falciparum reticulocyte binding protein homologue 5-interacting protein, PfRipr, as a highly conserved blood-stage malaria vaccine candidate.
    Ntege EH; Arisue N; Ito D; Hasegawa T; Palacpac NMQ; Egwang TG; Horii T; Takashima E; Tsuboi T
    Vaccine; 2016 Nov; 34(46):5612-5622. PubMed ID: 27692771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.